By Kamal Choudhury Feb 25 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Eton Pharmaceuticals' first-of-its-kind liquid therapy for a rare hormonal disorder, offering a more ...
“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...